Author

Brian G. Feagan 1

1 Robarts Research Institute, University of Western Ontario, Robarts Clinical Trials Inc., London, ON, Canada

A POOLED SAFETY ANALYSIS FROM THE USTEKINUMAB CROHN?S DISEASE AND PSORIATIC DISEASES PHASE 2 AND 3 CLINICAL TRIAL PROGRAMS

Subrata Ghosh, Bruce E. Sands, Willem de Villiers, Elyssa Ott, Christopher Gasink, Yinghua Lang, Philippe Szapary, Douglas Jacobstein, Brian G. Feagan

A RANDOMIZED, DOUBLE-BLIND, MULTICENTER STUDY TO EXPLORE THE EFFICACY OF ORAL GED-0301 (MONGERSEN) ON ENDOSCOPIC ACTIVITY AND CLINICAL EFFECTS IN BOTH TNF-NAIVE AND TNF-EXPERIENCED SUBJECTS WITH ACTIVE CROHN?S DISEASE

Brian G. Feagan, Bruce E. Sands, Guillermo Rossiter, Xiaobin Li, Keith Usiskin, Xiaojiang Zhan, Jean-Frederic Colombel

A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL OF OZANIMOD, AN ORAL S1P RECEPTOR MODULATOR, IN MODERATE TO SEVERE ULCERATIVE COLITIS: RESULTS OF THE MAINTENANCE PERIOD OF THE TOUCHSTONE STUDY

William Sandborn, Brian G. Feagan, Douglas C. Wolf, Geert R. D'Haens, Severine Vermeire, Stephen B Hanauer, Subrata Ghosh, Heather Smith, Matt Cravets, Paul A. Frohna, Richard Aranda, Sheila Gujrathi, Allan Olson

AN EXPERT CONSENSUS TO STANDARDIZE THE ASSESSMENT OF HISTOLOGIC DISEASE ACTIVITY IN CROHN'S DISEASE CLINICAL TRIALS

Ahmed Almradi, Christopher Ma, Geert R. D'Haens, William Sandborn, Claire Parker, Leonardo Guizzetti, Paula Borralho Nunes, Geert De Hertogh, Roger M. Feakins, Reena Khanna, Gregory Y. Lauwers, Aart Mookhoek, Reet Pai, Laurent Peyrin-Biroulet, Robert Riddell, Christophe Rosty, David F. Schaeffer, Mark Valasek, Brian G. Fe

ASSOCIATION BETWEEN PROPOSED DEFINITIONS OF CLINICAL REMISSION/RESPONSE AND WELL-BEING IN PATIENTS WITH CROHN'S DISEASE

William Sandborn, James D Lewis, Julian Panés, Edward V. Loftus, Jr, Geert R. D'Haens, ZHUQING YU, Bidan Huang, Ana P. Lacerda, Aileen L Pangan, Brian G. Feagan

CLINICAL OUTCOMES IN CONTINUOUS CLINICAL RESPONDERS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS: SUB-ANALYSES FROM THE PURSUIT-SC MAINTENANCE STUDY

W Reinisch, Brian G. Feagan, C Marano, R Strauss, Jewel Johanns, H Zhang, H Weng, R Yao, Dino Tarabar, Zbigniew Hebzda

CLINICAL REMISSION DEMONSTRATED WITH ORAL OZANIMOD IN THE OVERALL POPULATION AND ACROSS MULTIPLE SUBGROUPS OF PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS IN THE TOUCHSTONE TRIAL

Brian G. Feagan

Clinical Remission Demonstrated with Oral Ozanimod in the Overall Population and Across Multiple Subgroups of Patients with Moderately to Severely Active Ulcerative Colitis in the TOUCHSTONE Trial

Brian G. Feagan, William Sandborn, Geert R. D'Haens, Steve Hanauer, Douglas C. Wolf, Severine Vermeire, Subrata Ghosh, Annkatrin Petersen Jappelli, Steven Ye Hua, Kevin Shan, W Jerry Liu

EARLY AND SUSTAINED REMISSION AFTER TREATMENT WITH SC ADMINISTERED GOLIMUMAB IS ASSOCIATED WITH NORMALIZED HEALTH-RELATED QUALITY OF LIFE IN PATIENTS WITH MODERATE TO SEVERE ULCERATIVE COLITIS: POSTHOC-ANALYSIS FROM PURSUIT INDUCTION AND MAIN

Walter Reinisch, Brian G. Feagan, Colleen W. Marano, Richard S Strauss, C. Han, T Gathany, Jewel Johanns, Hongjie Zhang, Peter R. Gibson, John Collins, Paul Rutgeerts, Jean-Frederic Colombel, Brian G. Feagan, Gunnar Jarnerot, William Sandborn

Early Histologic Improvement Demonstrated with Oral Ozanimod in Patients with Moderately to Severely Active Crohn's Disease in the STEPSTONE Trial

Brian G. Feagan, Geert R. D'Haens, Keith Usiskin, W Jerry Liu, Rish K. Pai

Item 1 - 10 / 96
1
2 3 4 5 6 7
...
9 10